Product Images Erlotinib Hydrochloride

This package contains tablets with each tablet containing 100mg of Erlotinib base. The usual dosage information is found in the enclosed package insert. It is recommended to store at 25°C with excursions up to 30°C permitted. The package is resistant to chides. It has been manufactured by Alembic Pharmaceuticals Limited in Gujarat, India, and manufactured for Alembic Pharmaceuticals Inc. in Bridgewater, NJ. The product is Rx only with NDC 62332-566-30. The alphanumeric code includes Mifg. Lic. No. GI2512172 and GTIN: 00362332566303. There is also a coding area that is not to be printed.*

This package contains tablets of Erlotinib, with each tablet having a fin-coated cap and 150 mg of gefitinib free base. The usual dosage and complete prescription information can be found in the package inset. Store the package at a controlled room temperature between 25°C to 30°C. This package is chidesistant. The manufacturer is Alembic Pharmaceuticals Limited Formulation Division I from Gujarat, India. This medicine has been made for Alembic Pharmaceuticals, Inc. in NJ, USA. This medicine is available in a pack of 30 tablets, and the label has a unique NDC code and Mifg. Lic. No. GI2512172. Note that the coding area on the package must not be printed.*

These are tablets coated with fim that contain 25 mg of eotinb fee base. The usual dosage instructions are mentioned on the package insert. It can be stored at room temperature between 15 to 30°C (59° to 86°F) with excursions permitted. It is manufactured by Alembic Pharmaceuticals Limited in Gujarat, India and is formulated at Survey No. 84, 87, and 8, Panelay, Taluka Hal, Panchrahal. The manufacturer is Alembic Pharmaceuticals, Inc. with an address in Bridgewater, NJ. They come in a pack of 30 tablets with an NDC of 62332-565-30. Other details provided in the text are manufacturing licenses and a coding area.*

This text appears to be a table displaying the survival probability for two different treatment groups (Placebo and Erotind) over a span of several months. The table includes the number of patients at risk for each group at different timepoints. However, the text is not very legible and some characters are not recognized by , making it difficult to interpret the table accurately.*

This appears to be a survival probability chart indicating the number of patients at risk in a comparison between a placebo group and a group given erlotinib. The X-axis shows the overall survival in months and the Y-axis shows the number of patients at risk. However, some of the numbers and values are missing or unclear.*